PCP
GYRE icon

Proficio Capital Partners’s Gyre Therapeutics GYRE Stock Holding History

Proficio Capital Partners’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-18
Closed -$1K – 719
2019
Q2 		$1K Buy
+18
New +$1.13K ﹤0.01% 1737

Other funds holding GYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Proficio Capital Partners's GYRE Position: Q3 2019 in Review

Proficio Capital Partners sold out of Gyre Therapeutics (GYRE) in Q3 2019, closing a stake of 18 shares — an estimated $1K sold.

Proficio Capital Partners first reported a position in GYRE in Q2 2019 and held it in 1 quarter. The position peaked at $1K in Q2 2019. 42 funds tracked by Wall St. Rank hold GYRE as of Q3 2019.

  • Proficio Capital Partners reported no remaining Gyre Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Proficio Capital Partners sold 18 Gyre Therapeutics shares in Q3 2019, an estimated $1K.
  • Proficio Capital Partners first reported a position in Gyre Therapeutics in Q2 2019 and held it in 1 quarter.
  • Proficio Capital Partners's Gyre Therapeutics position peaked at $1K in Q2 2019.
  • 42 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q3 2019.

Based on Proficio Capital Partners's 13F filing for Q3 2019, filed 13 Nov 2019.